RAS genes are most commonly associated with gainof function mutations that promote oncogenic behavior. Activating mutations in KRAS occur in 90-95% cases of pancreatic ductal adenocarcinoma (PDAC) a deadly and highly metastatic disease. Currently the fourth leading cause of cancer death in the United States, PDAC presents with a dismal 5-year survival rate of less than 5% (1). Acquisition of KRAS mutation is regarded as an initiating event in the development of PDAC, but what is the role of the wild-type KRAS allele in disease initiation and progression?
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The human genome encodes three distinct RAS genes: KRAS, NRAS, and HRAS. The KRAS gene has two splice variants of the 4th exon that give rise to KRAS4A and KRAS4B (2) . The majority of KRAS mutations occur at either codons G12, G13 or Q61. When KRAS is mutated, both KRAS4A and KRAS4B expressed from the mutant allele will be mutated (3). Alteration of codon 12 changes glycine to aspartic acid (G12D) and locks KRAS in the constitutively active and therefore oncogenic configuration (2) . Oncogenic KRAS engages downstream effectors including the RAF-mitogen activated protein kinase (MAPK) and phosphoinositide-3-kinase (PI3K) pathways, which promotes enhanced cellular proliferation, survival, and motility all of which are commonly perturbed in cancer (2 The progression of PDAC has been well documented by histologically distinct precursor lesions called pancreatic intraepithelial neoplasia (PanIN) which harbor many of the same genetic aberrations found in the cancer (5) this was the preferred evolutionary mechanism upon homozygous Cdkn2a loss (4). The consequences of Cdkn2a loss in pancreatic tumorigenesis have been described previously in the seminal paper by Qiu and colleagues (6) . The inactivation of Cdkn2a alone in a mouse model was not sufficient to initiate pancreatic tumorigenesis but required simultaneous Kras G12D activation (6) . All of the compound mice with pancreas specific Cdkn2a inactivation and Kras G12D activation developed the full spectrum of mPanIN lesions and mPDAC with metastatic burden consistent with the human disease (6) . Similar to the work described by Mueller et al. The inhibitory effect of wild-type KRAS was found to be caused by dimerization with mutant KRAS. A dimerizationdeficient wild-type KRAS was unable to impart a growthinhibitory effect on mutant KRAS (7). In summary, the Mueller et al. paper proposes a "comprehensive conceptual framework" for the molecular mechanisms involved in the initiation and development of PDAC. Since gain-of-function mutation in RAS genes are among the most common events in human tumorigenesis (9) , the importance of the Mueller et al. study extends beyond pancreatic cancer. The work emphasizes defining principles of RAS-driven oncogenesis and corroborates observations seen in mutant RAS-driven mouse models of tumorigenesis and patient tumors that KRAS WT likely serves as a tumor suppressor. However, the function of wild-type RAS is complicated by the expression of multiple RAS isoforms and likely is inhibitory only to the oncogenic RAS of the same isoform (2) . Future therapeutics aimed at targeting KRAS may need to consider targeting oncogenic KRAS specifically without inhibiting wild-type KRAS function or gene dosage.
